Conditional survival and the choice of conditioning set for patients with colon cancer: An analysis of NSABP trials C-03 through C-07

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2544-2548

  Zamboni, Beth A ^a   Yothers, Greg ^a   Choi, Mehee ^a   Fuller, Clifton D ^a   Dignam, James J ^a   Raich, Peter C ^a   Thomas Jr , Charles R ^a   O'Connell, Michael J ^a   Wolmark, Norman ^a   Wang, Samuel J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERFERON; LEVAMISOLE; UFT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SURVIVAL RATE; AGE; COLON TUMOR; HEALTH CARE QUALITY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AGE FACTORS; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; UNITED STATES;

EID: 77956413529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0573     Document Type: Article

References (37)

1. Henson DE, Ries LA: On the estimation of survival. Semin Surg Oncol 10:2-6, 1994 (Pubitemid 24053282)
2. Gloeckler Ries LA, Reichman ME, Lewis DR, et al: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541-552, 2003
3. Davis FG, McCarthy BJ, Freels S, et al: The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer 85:485-491, 1999 (Pubitemid 29051306)
4. Hwang SL, Yang YH, Lieu AS, et al: The conditional survival statistics for survivors with primary supratentorial astrocytic tumors. J Neurooncol 50:257-264, 2000
5. Lin CL, Lieu AS, Lee KS, et al: The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 60:402-406, 2003; discussion, 406
6. Fuller CD, Wang SJ, Thomas CR Jr, et al: Conditional survival in head and neck squamous cell carcinoma: Results from the SEER dataset 1973- 1998. Cancer 109:1331-1343, 2007
7. Henson DE, Ries LA, Carriaga MT: Conditional survival of 56,268 patients with breast cancer. Cancer 76:237-242, 1995
8. Meng L, Maskarinec G, Lee J: Ethnicity and conditional breast cancer survival in Hawaii. J Clin Epidemiol 50:1289-1296, 1997 (Pubitemid 27501065)
9. Christensen LH, Engholm G, Ceberg J, et al: Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by patho-anatomical variables? A population-based study. Eur J Cancer 40:1233-1243, 2004
10. Wang SJ, Luh JY, Fuller CD, et al: Impact of ethnicity on conditional survival of breast cancer patients: Analysis from the SEER dastabase. 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 3090)
11. Wang SJ, Luh JY, Fuller CD, et al: Geographic variation in conditional survival for breast cancer patients: A SEER database analysis. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-17, 2006 (abstr 6058)
12. Merrill RM, Henson DE, Barnes M: Conditional survival among patients with carcinoma of the lung. Chest 116:697-703, 1999
13. Skuladottir H, Olsen JH: Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol 21:3035-3040, 2003 (Pubitemid 46606282)
14. Wang SJ, Fuller CD, Thomas CR Jr: Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol 2:180-190, 2007 (Pubitemid 47181322)
15. Fuller CD, Wang SJ, Kachnic L, et al: Conditional survival of gallbladder adenocarcinoma treated with radiotherapy: Analysis from the SEER database. Int J Radiat Oncol Biol Phys 63:S274, 2005
16. Thomas CR, Fuller CD, Starling GD, et al: Conditional survival in gallbladder carcinoma: Results from the SEER 11 dataset. J Clin Oncol 24:210s, 2006 (abstr 4130)
17. Wang SJ, Emery R, Fuller CD, et al: Conditional survival in gastric cancer: A SEER database analysis. Gastric Cancer 10:153-158, 2007 (Pubitemid 47547297)
18. Merrill RM, Henson DE, Ries LA: Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 41:1097-1106, 1998
19. Wang S, Zamboni B, Wieand H, et al: Conditional survival for patients with colon cancer: An analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials C-03 through C-06. J Clin Oncol 24:302s, 2006 (abstr 6005)
20. Wang SJ, Fuller CD, Emery R, et al: Conditional survival in rectal cancer: A SEER database analysis. Gastrointestinal Cancer Res 1:84-89, 2007
21. Luh J, Wang S, Fuller C, et al: A SEER database analysis of conditional survival for prostate cancer patients. J Clin Oncol 24:637s, 2006 (abstr 14506)
22. Choi M, Fuller CD, Thomas CR Jr, et al: Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001. Gynecol Oncol 109:203-209, 2008
23. Moller MB, Pedersen NT, Christensen BE: Conditional survival of patients with diffuse large B-cell lymphoma. Cancer 106:2165-2170, 2006 (Pubitemid 43673238)
24. Klish DS, Wang SJ, Kimler BF, et al: Improved prognosis with time after diagnosis for patients with anal cancer. Presented at the American Radium Society, 88th Annual Meeting, Wailea, HI, May 6, 2006
25. Kim E, Wang SJ, Fuller CD, et al: Conditional survival for patients with thymic carcinoma from the SEER database. Presented at American Thoracic Society International Conference, San Francisco, CA, May 20, 2007 (abstr 5420)
26. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al: Prognosis for long-term survivors of cancer. Ann Oncol 18:1408-1413, 2007 (Pubitemid 47305016)
27. Kato I, Severson RK, Schwartz AG: Conditional median survival of patients with advanced carcinoma: Surveillance, epidemiology, and end results data. Cancer 92:2211-2219, 2001
28. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005 (Pubitemid 46211509)
29. van Houwelingen HC, Putter H: Dynamic predicting by landmarking as an alternative for multistate modeling: An application to acute lymphoid leukemia data, Lifetime Data Anal 14:447-463, 2008
30. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
31. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999 (Pubitemid 29517927)
32. Wolmark N, Bryant J, Smith R, et al: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol C-05. J Natl Cancer Inst 90:1810-1816, 1998
33. Lembersky BC, Wieand HS, Petrelli NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059-2064, 2006 (Pubitemid 46622115)
34. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
35. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence: SEER 17 Regs Limited-Use, November 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. http://canques .seer.cancer.gov/ surv2004/Canques.cfg
36. Bryant J, Fisher B, Gündüz N, et al: S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51:239-253, 1998 (Pubitemid 29054557)
37. Gill S, Sargent D: End points for adjuvant therapy trials: Has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 11:624-629, 2006